Quick Answer
Sunshine Biopharma Inc. reported Net Income of -$5.13 million for fiscal year 2024.
Sunshine Biopharma Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$5.13M | -13.9% |
| 2023 | -$4.51M | +83.2% |
| 2022 | -$26.74M | -115.0% |
| 2021 | -$12.44M | -346.7% |
| 2020 | -$2.78M | -67.7% |
| 2019 | -$1.66M | +23.0% |
| 2018 | -$2.16M | -107.3% |
| 2017 | -$1.04M | +70.3% |
| 2016 | -$3.50M | -111.5% |
| 2015 | -$1.65M | +14.5% |
| 2014 | -$1.93M | +22.4% |
| 2013 | -$2.49M | -251.9% |
| 2012 | -$708.0K | -27.3% |
| 2011 | -$556.2K | -3.5% |
| 2010 | -$537.4K | +17.3% |
| 2009 | -$650.1K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$883.8K | +26.2% | +50.1% |
| June 30, 2025 | -$1.77M | -258.3% | -50.1% |
| March 31, 2025 | -$1.18M | +8.1% | +1.5% |
| September 30, 2024 | -$1.20M | -83.9% | -142.3% |
| June 30, 2024 | -$494.3K | +45.2% | +61.5% |
| March 31, 2024 | -$1.28M | +24.6% | -97.1% |
| September 30, 2023 | -$651.5K | +55.3% | +27.8% |
| June 30, 2023 | -$902.1K | -67.4% | +47.0% |
- Sunshine Biopharma Inc. showed a decrease of -13.9% in Net Income compared to the prior fiscal year.
- Over the 2009–2024 period, Sunshine Biopharma Inc.’s net income has declined by 689.7% (from -$650.1 thousand to -$5.13 million).
- The most recent figure is from Sunshine Biopharma Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: